In a high-stakes pivot that signals the maturation of AI-driven biotechnology, the startup Cellular Intelligence (formerly known as Somite AI) has officially acquired the global rights to STEM-PD, a pioneering clinical-stage cell therapy for Parkinson’s disease, from pharmaceutical titan Novo Nordisk.
The transaction is more than a simple asset transfer; it represents a strategic alignment between traditional big pharma’s clinical rigor and the high-speed, predictive capabilities of artificial intelligence. Under the terms of the deal, Novo Nordisk will retain an equity stake in the startup, alongside ongoing milestone and royalty rights, effectively betting that Cellular Intelligence’s proprietary foundation models can accelerate the commercialization of a therapy that has been over a decade in the making.
The Main Facts: A New Chapter for STEM-PD
The acquisition places STEM-PD—an allogeneic stem cell-derived therapy designed to replace lost dopamine-producing neurons in Parkinson’s patients—firmly in the hands of a company whose core mission is to transform cell biology from an era of "trial-and-error" into a precise engineering discipline.
Cellular Intelligence, founded in 2023, has rapidly emerged as a leader in the "tech-bio" space. With over $60 million in backing from heavyweights such as Khosla Ventures, AMD Ventures, the Chan Zuckerberg Initiative (CZI), and SciFi VC, the company is building sophisticated foundation models capable of predicting how cells behave across millions of experimental perturbations. By applying this computational power to the STEM-PD manufacturing process, the company aims to overcome the "black box" nature of cell differentiation protocols.
Chronology: From Academic Labs to Clinical Reality
The journey of STEM-PD is a testament to the power of international collaboration. The foundation for the therapy was laid at Lund University in Sweden, where renowned neuroscientist Malin Parmar pioneered methods to convert embryonic stem cells into the specific dopaminergic neurons that are progressively destroyed by Parkinson’s disease.
- 2010s – 2022: Long-term preclinical development takes place through a consortium involving Lund University, the University of Cambridge, Imperial College London, and Skåne University Hospital, supported by Novo Nordisk and various European research grants.
- February 2023: The first human patient receives the STEM-PD transplant, marking a historic milestone in neuroregenerative medicine.
- 2024: Nature Medicine highlights the STEM-PD trial as one of the 11 clinical studies set to shape the future of medical practice.
- Late 2025 – Early 2026: Discussions between Cellular Intelligence CEO Micha Breakstone and Novo Nordisk executive Jacob Petersen culminate in the current acquisition agreement, catalyzed by a shared vision of scaling cell therapy manufacturing.
Supporting Data: The Unmet Need in Parkinson’s
Despite two centuries of clinical observation—dating back to James Parkinson’s initial 1817 description of "shaking palsy"—the medical community has struggled to move beyond symptom management. While the introduction of Levodopa in 1970 provided a breakthrough in controlling motor symptoms, it does not halt the underlying neurodegeneration.
The economic and human costs are staggering. According to 2024 reports, the economic burden of Parkinson’s and related atypical parkinsonism in the United States has surged to over $82 billion annually, significantly outpacing previous long-term projections. While the Michael J. Fox Foundation has funneled over $3 billion into research and is currently tracking 151 different clinical treatments, the field remains littered with failed attempts to halt disease progression, particularly among strategies targeting alpha-synuclein proteins.
The shift toward cell replacement therapy, therefore, is fundamentally different. As Nuno Mendonça, M.D., the newly appointed Chief Medical Officer at Cellular Intelligence, notes: "Most of the current investigation is devoted to disease modification, and most of it fails. Cell therapy works on a different principle entirely: you’re basically substituting what the patients are missing."
Official Responses and the "Human" Element
For Micha Breakstone, the deal is the culmination of a lifelong professional goal. In an interview, he described the acquisition as the "very best day" of his career, emphasizing the human impact of the work.
"I told my wife that this is the moment we’ve been working toward," Breakstone said. "It’s the realization that we are much, much closer to the ultimate goal, which is reducing suffering and touching patients’ lives."
The relationship with Novo Nordisk was fostered over several months, rooted in a mutual respect for the complexities of the field. Breakstone credited his early outreach to Jacob Petersen, a long-time Novo Nordisk executive, for setting the stage. "He immediately captivated me with his vision and his deep understanding of the field," Breakstone noted. "We have been engaging with Novo for the last five months, building the trust required to hand over such a critical asset."
Implications: Engineering the "Recipe" for Cell Success
The core value proposition for Cellular Intelligence lies in its ability to optimize the "recipes" of cell differentiation. Manufacturing these cells is a delicate, time-sensitive process that requires pluripotent cells to be exposed to specific growth factors at precise intervals.
The Power of Temporal Resolution
Breakstone argues that standard manufacturing protocols are hyper-sensitive to minor fluctuations. "The protocols… are extremely sensitive to very minor changes and tweaks," he explained. "Very slight tweaks can end up in outsized deltas in terms of the profile of the cell. You can imagine that an exposure of six hours versus 10 hours to a certain biological growth factor might produce a very different viability window."
Cellular Intelligence’s platform differentiates itself through "temporally resolved" data. Unlike static snapshots, their AI tracks cell behavior over time, mimicking the scaling laws that propelled Large Language Models (LLMs) to prominence. By understanding the "signaling history" of a cell, the company can refine the production process, potentially increasing the viability of the final cell product.
Economic and Clinical Efficiency
The implications for manufacturing are twofold:
- Cost and Yield: A 10% increase in the viability window could translate to a roughly 9% decrease in the cost of goods, as it allows for more efficient extraction from reactors and more precise vial filling.
- Clinical Scalability: Improved cell quality and extended viability windows make the surgical administration of these therapies more feasible, simplifying the complex logistics of transplanting living cells into a patient’s brain.
As the company integrates the STEM-PD program, the focus will remain on the delicate balance between high-tech innovation and rigorous patient safety. With Nuno Mendonça bringing his experience from the successful development of Zolgensma to the team, Cellular Intelligence is well-positioned to navigate the regulatory and clinical hurdles ahead.
Looking Forward: A New Era for Neurodegeneration
The acquisition of STEM-PD by Cellular Intelligence marks a significant moment in the evolution of biotechnology. By marrying the deep, biological expertise of the European academic network with the high-throughput, predictive power of AI foundation models, the company is attempting to solve one of the most stubborn problems in medicine.
If the "engineering" approach to cell therapy succeeds, it could set a new precedent for how companies approach neurodegenerative diseases. Rather than searching for a "magic bullet" drug, the focus is shifting toward the precise, reproducible, and scalable manufacturing of the very biological components that the human body has lost. As the industry watches the progress of STEM-PD under its new stewardship, the broader hope remains clear: that the marriage of code and biology will finally offer a path to stop—and perhaps one day reverse—the progression of Parkinson’s disease.
About the Author
